Funding opportunities

New Technology for the Derivation of Human Pluripotent Stem Cell Lines for Clinical Use

Funding Type: 
New Cell Lines
Grant Number: 
RL1-00667
Principle Investigator: 
Funds requested: 
$1 387 508
Funding Recommendations: 
Recommended
Grant approved: 
Yes
Public Abstract: 
Statement of Benefit to California: 
Review Summary: 
Executive Summary This proposal aims to generate new human embryonic stem cell (hESC) lines derived under defined, xeno-free conditions while testing methods to improve derivation efficiency. This proposal also aims to generate induced pluripotent stem cells (iPSC) under similar culture conditions, initially using the established methods employing integrating lentiviral vectors, followed by testing alternate approaches to induce pluripotency that may be more compatible with clinical use. Once established, both cell populations, hESC and iPSC, will be rigorously characterized and compared using immunological, molecular, and biochemical approaches. The proposed aim to more carefully define hESC culture conditions addresses an important step towards generating hESC that can be used clinically, and its feasibility is supported by excellent preliminary data on defined culture conditions. Furthermore, a careful comparison of hESC and iPSC is needed – the enthusiasm for the latter may still be premature and studies such as this are crucial. It is essential, as is proposed in this application, to compare cells that have been treated in the same way. Equally, the development of new technologies to generate iPSC is required, given that cells with multiple viral insertions will not be suitable for clinical applications. Minor weaknesses of this proposal are the lack of detail in the description of the proposed small molecule approach, and the observation that the proposed cytoplast approach appears very inefficient. However, these can be improved and are not central to the key goals of the grant. This is a very straightforward and highly structured application. The experimental methods are broad, but clearly delineated, and the timelines proposed are feasible. The principal applicant is a highly experienced and pioneering stem cell biologist who has extensive experience in the characterization and differentiation of human pluripotent stem cells and has published extensively in the area of hESC. S/he has assembled a very accomplished team, although the reviewers were concerned that both the applicant and a crucial collaborator seem already heavily committed to other work. The cell lines derived under this project will be distributed to academic groups under a simple MTA at no cost to collaborative research groups. In addition, the cell lines will also be banked in the UK stem cell bank. Reviewer Synopsis There are two primary aspects of this project. The first is to generate new human embryonic stem cell lines using defined culture conditions, and secondly to use the new technology of induced pluripotency to generate equivalent iPS cell lines. Once established, both cell populations will be rigorously characterized and compared using immunological, molecular, and biochemical approaches. Reviewer One Comments Significance: To date most human embryonic stem cell lines have been derived using mouse or human feeders in the presence of serum or other animal products. Therefore there is a pressing need for more carefully defined culture conditions. The strength of this project is previous publications in the propagation of the existing cell lines using highly defined culture conditions. One goal of this project will be to generate new human embryonic stem cell lines using defined culture conditions. The second major aim of the project is to further assess the generation of iPS cells using both existing protocols as well as the use of non-integrating lentiviruses, cytoplasmic fusion, and induction of pluripotency without genetic modification. Feasibility: This is a very straightforward and highly structured application to generate new populations of human ES cells either from human embryos or through induction of pluripotency from human somatic cells. The principal applicant is a highly experienced and pioneering stem cell biologist who has published extensively in the area of human ES cells. The first goal of this project is to generate new human ES cells using serum free chemically defined media in combination with chemically defined extracellular matrix proteins. The applicants have previously published on the successful propagation of pre-existing hES cell lines in defined media and this will be used as a starting point for attempting to derive new hES cell lines. The second major aim of the project is to use methods recently published by several groups shown to be capable of converting human somatic cells into ES like cells using genetic modification. The applicants propose to follow initially the established methods using integrating lentiviral vectors but will also attempt to achieve similar cells using non-integrating lentiviral vectors. They will also attempt an alternate approach to achieve reprogramming without genetic modification using fusion of somatic cells with enucleated cytplasts of ES cells. Once each type of cell line has been established, the applicants will rigorously compare and contrast hES cells and IPS derived hES-like cells using standard and well characterized methodology. The applicant has been one of the pioneers in human ES cell biology and has extensive experience in the characterization and differentiation of human pluripotent stem cells. Responsiveness to RFA: Methodologies to characterize the human embryonic stem cell lines defined in this project are well articulated and within the expertise of the applicant. In addition, cell lines derived under this project will be distributed to academic groups under a simple MTA at no cost to collaborative research groups. In addition the cell lines will also be banked in the UK stem cell bank. Reviewer Two Comments Significance: This proposal aims to generate new hES cell lines derived under defined, xeno-free conditions while testing methods to improve derivation efficiency - these are important steps towards generating hES cells that can be used clinically. This proposal also aims to generate iPS cells under similar conditions while testing alternate approaches to induce pluripotency that may be more compatible with clinical use than the standard lentiviral approach. Feasibility: The PI and the team he has assembled is very accomplished in all aspects of human embryonic stem cell biology. The experimental methods are broad, but clearly delineated. Novel hES cell lines will serve as controls to iPS lines which will be generated using traditional (lentiviral) and alternate methods. Extensive characterization will be performed on the lines to study differences between iPS and hES cells. The timelines proposed are feasible. Responsiveness to RFA: Both hES and iPS cells under defined, xeno-free conditions will be generated and made available to other researchers. This meets the RFA, while also advancing the general understanding of iPS cells. Reviewer Three Comments Significance: A careful comparison of hES cells and iPS cells is needed – the enthusiasm for the latter may still be premature and studies such as this, while seeming pedestrian, are crucial. Equally, the development of new technologies to generate iPS cells is required, given that cells with multiple viral insertions will not be suitable for clinical applications. Feasibility: Strengths are feasibility and the recognition that defined cells and substrates are required if GMP grade hES or iPS cells are to be derived. The point made here that it is essential to compare cells that have been treated in the same way, for example, use of same substrates, is important. Weaknesses are the lack of development of the small molecule approach, and the observation that the cytoplast approach appears very inefficient. However, these can be improved and are not central to the key goals of the grant. Responsiveness to RFA: Excellent
Conflicts: 

© 2013 California Institute for Regenerative Medicine